Carcinoma, Non-small Cell Lung
Conditions
Brief summary
The objective of this study is to investigate the effect of docetaxel monotherapy and the combination of docetaxel intercalated erlotinib in patients with relapsed EGFR wild type, ALK negative non squamous cell carcinoma.
Detailed description
The aim of this study is to investigate the effect of docetaxel monotherapy and the combination of docetaxel intercalated erlotinib in patients with relapsed EGFR wild type, ALK negative non squamous cell carcinoma. As pemetrexed is standard first line treatment, the combination of erlotinib docetaxel in non-squamous NSCLC should be investigated as second line treatment. Also the question has to be answered whether the combination outperforms monotherapy treatments. After stratification for ECOG-performance status (0-1), response to prior treatment (CR, PR, SD versus PD), treatment free interval after platinum based therapy (\<6 months versus \>6 months) and maintenance, patients will be centrally randomized to receive either docetaxel (arm A) or docetaxel plus erlotinib (arm B).
Interventions
DRUGDocetaxel
75mg/m2
DRUGErlotinib
150mg/day
Sponsors
Dutch Society of Physicians for Pulmonology and Tuberculosis
The Netherlands Cancer Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically or cytologically confirmed EGFR wild type, ALK negative, non-squamous cell carcinoma, locally advanced and metastatic disease stage IIIB and IV. Evidence of disease progression after one cytotoxic treatment platinum containing regimen. Immunotherapy pretreatment is allowed 2. Complete recovery from prior chemotherapy side effects to \< Grade 2. 3. At least one unidimensionally measurable lesion meeting RECIST criteria. 4. ECOG PS 0-1. 5. Age ≥ 18 years. 6. Adequate organ function, including: * Adequate bone marrow reserve: ANC \> 1.5 x 109/L, platelets ≥ 100 x 109/L. * Hepatic: bilirubin ≤1.5 x ULN (upper limit normal), AP, ALT, AST ≤ 1.5 x ULN. AP, ALT, and AST ≤5 x ULN is acceptable if the liver has tumor involvement. * Renal: calculated creatinine clearance ≥ 40 ml/min based on the Cockcroft-Gault formula. 7. Male and female patients with reproductive potential must use an approved contraceptive method, if appropriate. Female patients with childbearing potential must have a negative serum pregnancy test within 7 days prior to study enrollment. 8. Signed informed consent. 9. Patient compliance and geographical proximity that allow adequate follow up. 10. Patients who have undergone cranial irradiation for brain metastases more than 4 weeks before inclusion in our protocol, provided that they are clinically fit to undergo second line treatment
Exclusion criteria
1. Pregnant or lactating women. 2. Patients with medical risks because of non-malignant disease as well as those with active uncontrolled infection. 3. Documented brain metastases unless the patient has completed local therapy for central nervous system metastases at least 4 weeks before enrollment and has been off corticosteroids for at least two weeks before enrollment. Prophylactic irradiation at least 4 weeks prior to enrollment is accepted. 4. Maintenance treatment with erlotinib or other TKI (Tyrosine Kinase Inhibitor), or docetaxel. Maintenance treatment with pemetrexed is allowed. Previous treatment with an EGFR-TKI or docetaxel within 6 months prior to enrollment. 5. Inability or unwillingness to take dexamethasone. 6. Concomitant treatment with any other experimental drug under investigation. 7. Patients experiencing disease progression within 2 months after the start of platinum based chemotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival | from the date of randomization to the first date of progression of disease or of death from any cause up to 24 months after last treatment administration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| quantitative and qualitative adverse events | from the date of randomization until resolution or stabilization of the event and up to 30 days after the last study medication/treatment | Adverse events will be graded according to NCI Common Toxicity Criteria version 4.03 |
| response rates | Every six weeks from date of randomization until the date of first documented progression or date of death from any cause up to 24 months after last treatment administration | — |
| duration of response | from the date of the first objective status assessment of a complete or partial response to the first date of progression of disease or death from any cause up to 24 months after last treatment administration | — |
| overall survival | from the date of randomization to the date of death from any cause up to 24 months after last treatment administration | Evaluation of overall survival (OS) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Erlotinib dose level variance in blood | Every six weeks from randomisation up until last treatment administration (up until 48 weeks) | Therefore in patients on erlotinib every 6 weeks through dose levels in blood will be determined |
Countries
Netherlands
Outcome results
None listed